Tarpon Springs, Florida Wednesday, June 4, 2025, 12:00 Hrs [IST] ...

Allarity Therapeutics ( ($ALLR) ) has shared an update. On June 2, 2025, Allarity Therapeutics announced the enrollment of the first patient in ...

Therapeutics announced that the first patient has been enrolled in its new Phase 2 clinical trial protocol of stenoparib for the ...

The trial is expected to generate significant clinical data by late summer 2026. Allarity plans to pursue multiple advantaged ...

Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment ...

TARPON SPRINGS, Fla., May 12, 2025 -- Allarity Therapeutics, Inc. (ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT ...

May 12, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the“Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib-a differentiated ...

TARPON SPRINGS, Fla., May 9, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a ...